Welcome : Guest

Ligand Pharmaceuticals, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Ligand Pharmaceuticals, Inc., which is principally involved in Biopharmaceuticals Business. Illustrated with 151 tables, the report showcases the company's recent news stories and events, key markets and market position as against its competitors operating in the industry.

Code: PCP-05472
Price: $3500
Company Type: Public
Pages: 153
Date: February 2017
Market Data Tables: 151

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Biopharmaceuticals......2
Table 1: Biopharmaceuticals Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Norditropin, NovoSeven, Turoctocog Alpha, and Others......2
Cancer Drugs......3
Table 2: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......3
Table 3: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......4
Cancer Market......5
Table 4: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......5
Table 5: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......6
Table 6: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......7
Table 7: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......8
Table 8: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......9
Table 9: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......10
Table 10: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......11
Table 11: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......12
Cancer Patients......13
Table 12: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......13
Table 13: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......14
Table 14: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......15
Table 15: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......16
Table 16: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......17
Table 17: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......18
Table 18: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......19
Table 19: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......20
Table 20: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......21
Table 21: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......22
Table 22: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......23
Table 23: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......24
Table 24: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......25
Table 25: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......26
Table 26: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......27
Table 27: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......28
Table 28: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......29
Table 29: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......30
Table 30: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......31
Table 31: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......32
Table 32: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......33
Cervical Cancer......34
Table 33: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......34
Table 34: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......35
Hematological Cancer......36
Table 35: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......36
Skin Cancer......37
Table 36: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......37
Cancer-Associated Mucositis......38
Table 37: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......38
Chronic Myelogenous Leukemia (CML)......39
Table 38: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......39
Multiple Myeloma......40
Table 39: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......40
Table 40: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......41
Dermatological Drugs......42
Table 41: Dermatological Drug Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Acne, Alopecia, Atopic Dermatitis, Herpes, Psoriasis, Rosacea, Skin Cancer, and Skin Infections......42
Table 42: Dermatology Drugs Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for France, Germany, Italy, Japan, Spain, UK, US, and Rest of World......43
Table 43: Dermatology Market by Category in the US (2015) - Percentage Share Breakdown by Value for Genericised, Off-Patent but No Generics, On-Patent, and Others......44
Table 44: Dermal Substitutes Chronic Wound Market by Category in the US (2015) - Percentage Share Breakdown by Value for Diabetic Foot Ulcer, Pressure Ulcer and Venous Leg Ulcer......45
Table 45: Prevalence & Severity of Actinic Keratoses Market by Category in the US (2015) - Percentage Share Breakdown by Value for Minimal, Moderate, Severe, and Others......46
Seizure Disorders......47
Table 46: Seizure Disorder Market by Type of Drug in the US (2015) - Percentage Share Breakdown by Value for Carbamazepine, Clonazepam, Gabapentin, Lamotrigine, Levetiracetam, Valproic Acids and Others......47
Diabetes......48
Table 47: Diabetes Market by Region Worldwide (2015) - Percentage Share Breakdown for Africa, Europe, Middle East & North Africa, North America & Caribbean, Southeast Asia, and Western Pacific......48
Table 48: Diabetes Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Insulin Type‐1 Diabetes, Insulin Type‐2 Diabetes, Dipeptidyl Peptidase 4, (DPP4), Glucagon-like Peptide-1 (GLP‐1), Dipeptidyl Peptidase 4, (DPP4) + Biguanide, and Others* (includes Sodium-Glucose Co-Transporter-2 (SGLT2), Biguanide, Sulfonylurea, Alpha-Glucosidase Inhibitors, Peroxisome Proliferator-Activated Receptor (PPAR)......49
Table 49: Diabetes Care Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Human Insulins, Modern Insulins, Victoza, and Others......50
Table 50: Type-II Diabetes Treatments Market Worldwide (2015-2020) in US$ Million......51
Table 51: Type II Diabetes Market by Treatment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-IV Inhibitors, GLP-1 Agonists, SGLT-2 Inhibitors and Thiazolidinediones......52
Table 52: Type II Diabetes Market by Insulin Treatment Worldwide (2015) - Percentage Share Breakdown by Value for Diet and Exercise Only, Insulin and Orals and Insulin Only......53
Table 53: Diabetes Healthcare Market by Category in the US (2015) - Percentage Share Breakdown by Value for Anti -Diabetic Agents & Supplies, Doctor Office Visits, Hospital Care, Nursing/Residential Facility Stays, Prescription Medication, and Others......54
Table 54: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown for Insulin Pumps, and Multiple Daily Injections......55
Table 55: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown by Value for Type 1, and Type 2......56
Table 56: No. of Diabetes Patients by Medication in the US (2015) - Percentage Share Breakdown for Insulin and Oral Medication, Insulin Only, No Medication, and Oral Medication Only......57
Diabetes Drugs......58
Table 57: Diabetes Drug Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-4 Inhibitor, GK Activator, GLP-1 Agonist, GPCR Agonist, IL- Receptor Antagonist, Insulin Analogue, PPAR Agonist, SGLT-2 Inhibitor, and Others......58
Table 58: Diabetes/Metabolic Drugs Market by Category Worldwide (2015) - Percentage Breakdown by Value Sales for DPP-IV Inhibitors, Glitazones, GLP-1 Analogs, Insulins, Sulfonylureas, and Others......59
Table 59: Anti-Diabetic Drug Market by Treatment Class Worldwide (2015) - Percentage Share Breakdown by Value for Diet & Exercise, Incretion, Insulin and Oral Anti-Diabetic......60
Table 60: Antidiabetes Molecules Market by Drug Worldwide (2015) - Percentage Share Breakdown by Value for Metformin, Sulfonylureas, Thiazolidin Ediones and Others......61
Table 61: Anti-Diabetic Drugs Market in China (2015-2020) in RMB Million......62
Table 62: Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glinide, Insulin, Sulfonylureas, α-glucosidase Inhibitor, and Others......63
Table 63: Anti-Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Insulin Drugs and Non-Insulin Drugs......64
Table 64: Diabetes Drugs Market by Product Category in China (2015) - Percentage Share Breakdown by Value for Acarbose, Insulin, Melbine, and Other Diabetes Drugs......65
Table 65: Diabetic Drugs Market by Category in the US (2015) - Percentage Share Breakdown by Value for DPP-IV & SGLT-2, GLP-1, Insulins, and Others......66
Table 66: Diabetic Drugs Market by Non-Insulin Therapy in the US (2015) - Percentage Share Breakdown by Volume for Biguanides, DPP-4 Inhibitor, Human GLP-1 Analogs, SGLT-2 Inhibitor, Sulfonylureas, and Others......67
Table 67: Oral Diabetes Medicine Market in the US (2015) - Percentage Share Breakdown by Value Sales for Dipeptidyl Peptidase-4 (DPP4), Metformin, Sulfonylureas, and Others......68
Non-Insulin Anti-Diabetic Drugs......69
Table 68: Non-Insulin Anti-Diabetic Drugs Market by Product in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glucosidase Inhibitors, Nateglinide, Sulfonylurea and Others......69
Diabetic Macular Edema (DME)......70
Table 69: Diabetic Macular Edema (DME) Market by Drug Treatment Worldwide (2015) - Percentage Share Breakdown by Volume for Avastin, Laser Photocoagulation, Lucentis 0.3 mg, Steroids and Others......70
Table 70: Diabetic Macular Edema (DME) Anti Vascular Endothelial Growth Factor (VEGF) Market by Segment in the US (2015) - Percentage Share Breakdown by Volume for Avastin, Lucentis and Others......71
Insulin......72
Table 71: Insulin Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Aspart (Novolog), Detemir (Levemir), Glargine (Lantus), Glulisine (Apidra), Lispro (Humalog), and Rh Insulin......72
Table 72: Insulin Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Basal Insulins, Prandial Insulins and Pre-Mixed Insulin......73
Table 73: Insulin Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Fast Acting, Long Acting and Premix......74
Table 74: Insulin Market by Generation in China (2015) - Percentage Share Breakdown by Value for 1st Generation, 2nd Generation, and 3rd Generation......75
Table 75: Insulin Market by Product Type in the US (2015) - Percentage Share Breakdown by Value for Fast-Acting, Human, Long-Acting and Mix......76
DPP-4 Inhibitors......77
Table 76: DPP-4 Inhibitors Market by Product Category Worldwide (2015) - Percentage Share Breakdown by Value for Galvus & Galvumet (Novartis), Januvia & Janumet (MRK), Nesina & Kezano (Takeda), Onglyza & Kombiglyze (AZN/BMY) and Tradjenta & Jentadueto (BI/Lilly)......77
Table 77: DPP-4 Inhibitors Market in China (2015-2020) in RMB Million......78
Table 78: DPP-4 Inhibitors (Fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Galvusmet, Janumet, Janumet XR, Kombiglyze, Trajenta Duo and Zemimet......79
Table 79: DPP-4 Inhibitors (Non-fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Januvia, Nesina, Tradjenta, Zemiglo, and Others......80
Table 80: DPP-4 Inhibitors Market by Prescription in the US (2015) - Percentage Share Breakdown by Volume for Janumet (Sitagliptin + Metformin), Januvia (Sitagliptin), Kombiglyze XR (Saxagliptin + Metformin), Onglyza (Saxagliptin), and Others......81
Table 81: DPP-4 Inhibitors Market in the US (2015) in No. of Prescriptions......82
DPP-4 type Diabetes Drugs......83
Table 82: DPP-4 type Diabetes Drugs Market in Japan (2015) in Yen Million......83
Kidney Disease Drugs......84
Table 83: Traditional Chinese Medicine (TCM) Market for Kidney Ailments by Drug in China (2015) - Percentage Share Breakdown by Value Sales for Ambrette Capsule, Haikunshenxi Capsule, Shenyankangfu Tablet, Uremic Clearance Granule, Yinhuamiyangling and Others......84
Table 84: Kidney Disease Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp and Others......85
Table 85: Dialysis Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp, EPO alfa/beta biosimilars and Others......86
Table 86: Hemodialysis Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp, Epogen, and Others......87
Table 87: Chronic Kidney Disease Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp and Others......88
Table 88: Peritoneal Dialysis Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp, Epogen, and Others (Includes Mircera)......89
Table 89: New Patients with Kidney Failure by Cause in the US (2015) - Percentage Share Breakdown by Volume for Diabetes, High Blood Pressure and Others......90
Central Nervous System (CNS) Drugs......91
Table 90: Central Nervous System (CNS) Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Depression, Epilepsy, Narcotic Analgesics, Non-Narcotic Analgesics, Psychotic Disorders and Others......91
Table 91: Central Nervous System Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Anti-Migraine, Antipsychotics, Newer Antidepressants, Older Antidepressants, SNRI's, SSRI’s, Tranquilizers, and Others......92
Cardiology......93
Table 92: Cardiovascular Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for ACE Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, Anti-Arrhythmics, Anti-Thrombotics, Beta Blockers, Calcium Channel Blockers, Cholesterol, GP IIb/IIIa Inhibitors, Vasodilators, and Others......93
Table 93: Cardiology Market by Category in the US (2015) - Percentage Breakdown by Value Sales for ACE Inhibitors, Alpha Blockers, Anti-Arrhythmics, ARB's, Beta Blockers, Calcium Blockers, Cholesterol, Digitalis, Diuretics, Vasodilators, and Others......94
Table 94: Cardiology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Cardiac Rhythm Management & Congestive Heart Failure Devices, Cardiac Surgery, and Interventional Cardiology......95
Antivirals......96
Table 95: Antiviral Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others......96
Antibiotics......97
Table 96: Antibiotics Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, and Others......97
Table 97: Methicillin-Resistant Staphylococcus Aureus (MRSA) Antibiotics Market by Product Type Worldwide (2015) - Percentage Share Breakdown by Value Sales for Cubicin, Tygacil, Vancocin (Generic), Vibativ (Telavancin), and Zyvox......98
Table 98: Antibiotics Market by Category in China (2015) - Percentage Share Breakdown by Value Sales for Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, and Others......99
Table 99: Antibiotic Market by Drug Type in the US (2015) - Percentage Share Breakdown by Podiatrists Prescription for Cephalosporins, Macrolides, Penicillins, Quinolones, and Tetracyclines......100
Biopharmaceuticals......101
Table 100: Market Shares of Leading Biopharmaceutical Companies Worldwide (2014) - Percentage Breakdown by Volume (Installed Capacity) for Amgen Inc., Biogen Idec, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd., Lonza Group Ltd., Pfizer, Inc., Sanofi S.A., and Others......101
Table 101: Market Shares of Leading Biopharmaceutical Companies in the US (2015) - Percentage Market Share Breakdown by Value for Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals, Inc., Celgene Corporation, Gilead Sciences, Inc., Incyte, Corporation, Isis Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., and Others......102
Cancer Drugs......103
Table 102: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......103
Table 103: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......104
Table 104: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......105
Table 105: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......106
Table 106: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......107
Breast Cancer Drugs......108
Table 107: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......108
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......109
Table 108: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......109
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......110
Table 109: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......110
Table 110: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......111
Dermatological Products......112
Table 111: Market Shares of Leading Dermatological Product Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Johnson & Johnson, Pfizer, Inc., Reckitt Benckiser Plc, and Others......112
Table 112: Market Shares of Leading Dermatology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Biogen Idec, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, and Others......113
Table 113: Market Shares of Leading Therapeutic Dermatology (excluding Aesthetics) Medicine Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Inc. (ABBV), Galderma S.A., GlaxoSmithKline Plc (GSK), Johnson & Johnson, Merck & Co., Inc. (MRK), Pfizer, Inc. (PFE), Amgen, Inc. (AMGN), Valeant Pharmaceuticals Intl, Inc., Dermik Laboratories, and Others......114
Table 114: Market Shares of Leading Drugs for Treatment of Skin Infection in the US (2015) - Percentage Share Breakdown by Value for CUBICIN, VANCOMYCIN, ZYVOX IV and Others......115
Osteoporosis, Hormone Replacement, & Cancer Bone Loss Medicine......116
Table 115: Market Shares of Leading Osteoporosis, Hormone Replacement, & Cancer Bone Loss Medicine Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Amgen, Inc. (AMGN), Eli Lilly And Co (LLY), Merck & Co., Inc. (MRK), Novartis AG (NVS), Sanofi SA (SNY), Warner Chilcott Plc (WCRX), and Others......116
Diabetes Drugs......117
Table 116: Market Shares of Leading Diabetes Care Companies Worldwide (2014) - Percentage Breakdown by Value Sales for Bristol-Myers Squibb (Incl Amylin), Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi S.A. and Others......117
Table 117: Market Shares of Leading Diabetes Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Others......118
Table 118: Market Shares of Leading Anti-Diabetic Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Abbott Healthcare Pvt Ltd., Biocon Limited, Lupin Pharmaceuticals, Inc., MSD Pharmaceuticals Private Limited, Sanofi-Aventis Groupe, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., and Others......119
Insulin......120
Table 119: Market Shares of Leading Insulin Companies Worldwide (2014) - Percentage Breakdown by Value Sales for Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., and Others......120
Table 120: Market Shares of Leading Insulin Companies Worldwide (2014) - Percentage Breakdown by Volume Sales for Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., and Others......121
Table 121: Market Shares of Leading Fast & Intermediate Type Insulin Producers Worldwide (2015) - Percentage Share Breakdown by Value for Eli Lilly and Company, Novo Nordisk, Sanofi S.A. and Others......122
Table 122: Market Shares of Leading Long-Acting Insulin Producing Companies Worldwide (2015) - Percentage Share Breakdown by Value for Sanofi S.A., Wockhardt Ltd., and Others......123
Table 123: Market Shares of Leading Insulin Companies in China (2014) - Percentage Share Breakdown by Value for Eli Lilly and Company, GanLee Pharmaceutical Co., Ltd., Novo Nordisk, Sanofi S.A., Shanghai Fosun Pharmaceutical Group Co., Ltd., United Laboratories International Holdings Ltd. (The), Tonghua Dongbao Pharmaceutical Co., Ltd., and Others......124
Table 124: Market Shares of Leading Insulin Companies in China (2015) - Percentage Share Breakdown by Volume for Novo Nordisk, Tonghua Dongbao Pharmaceutical Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Others......125
Table 125: Market Shares of Leading Insulin Companies in Europe (2014) - Percentage Breakdown by Volume Sales for Novo Nordisk A/S, and Others......126
Table 126: Market Shares of Leading Insulin Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Biocon Ltd., Cadila Pharmaceuticals Ltd., Eli Lilly and Company India Pvt. Ltd., Lupin Pharmaceuticals, Inc., Novo Nordisk India Ltd., Pfizer India Ltd., Ranbaxy Laboratories Ltd., Sanofi India Ltd., Shreya Life Sciences Pvt. Ltd., USV Ltd., and Wockhardt Ltd.......127
Table 127: Market Shares of Leading Insulin Companies in Japan and Korea (2014) - Percentage Breakdown by Volume Sales for Novo Nordisk A/S, and Others......128
Table 128: Market Shares of Leading Insulin Companies in North America (2014) - Percentage Breakdown by Volume Sales for Novo Nordisk A/S, and Others......129
Second-Generation Insulin......130
Table 129: Market Shares of Leading Second-Generation Insulin Companies in China (2014) - Percentage Share Breakdown by Volume for Eli Lilly and Company, Novo Nordisk, The United Laboratories International Holdings, Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd.......130
Third-Generation Insulin......131
Table 130: Market Shares of Leading Third-Generation Insulin Companies in China (2014) - Percentage Share Breakdown by Volume for Eli Lilly and Company, Gan & Lee Pharmaceutical, Ltd., Novo Nordisk, and Sanofi S.A.......131
Human Insulin......132
Table 131: Market Shares of Leading Human Insulin Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Biocon Limited, Eli Lilly and Company India Pvt. Ltd., Novo Nordisk India Limited, Sanofi India Limited, Wockhardt Ltd., and Others......132
DPP-4 Inhibitors......133
Table 132: Market Shares of Leading DPP-4 Inhibitors Manufacturers by Value Sales Worldwide (2015) - Percentage Share Breakdown for Merck & Co., Inc. (Januvia/Janumet), Novartis AG (Galvus/Galvumet) and Takeda Pharmaceutical Co., Ltd. (Nesina/Kezano), and Others......133
Table 133: Market Shares of Leading DPP-4 Inhibitors for Treatment of Diabetes in Japan (2015) - Percentage Share Breakdown by Value for Equa, Glactiv, Januvia, Nesina, and Others......134
Table 134: Market Shares of Leading DPP-4 Drug Brands in China (2015) - Percentage Share Breakdown by Value for Galvus, Januvia, Onglyza, and Others......135
Sitagliptin/Metformin......136
Table 135: Market Shares of Leading Sitagliptin Brands by Value Sales in India (2015) - Percentage Share Breakdown for Istavel and Januvia......136
Table 136: Market Shares of Leading Sitagliptin Manufacturers by Value Sales in India (2015) - Percentage Share Breakdown for Merck & Co., Inc. and Sun Pharmaceutical Industries Ltd.......137
Table 137: Market Shares of Leading Sitagliptin/Metformin Brands by Value Sales in India (2015) - Percentage Share Breakdown for Janumet, and Others......138
Table 138: Market Shares of Leading Sitagliptin/Metformin Manufacturers by Value Sales in India (2015) - Percentage Share Breakdown for Merck & Co., Inc., and Others......139
Metformin......140
Table 139: Market Shares of Leading Metformin Suppliers in India (2015) - Percentage Share Breakdown by Value for Harman Finochem Ltd., USV Pharmaceuticals Ltd., Wanbury Limited and Others......140
Central Nervous System (CNS) Medicines......141
Table 140: Market Shares of Leading Central Nervous System Medicine Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AstraZeneca Plc (AZN), Bristol-Myers Squibb Company (BMY), Eli Lilly And Co (LLY), GlaxoSmithKline Plc (GSK), Johnson & Johnson, Merck & Co., Inc. (MRK), Novartis AG (NVS), Pfizer, Inc. (PFE), Shire Plc (SHPGY), and Others......141
Table 141: Market Shares of Leading Central Nervous System (CNS) Medicine Manufacturers by Value Sales in India (2015) - Percentage Breakdown for Torrent Pharmaceuticals Ltd., and Others......142
Ophthalmology Drugs......143
Table 142: Market Shares of Leading Ophthalmology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for F. Hoffmann-La Roche AG, Merck Ltd., Novartis AG, Pfizer, Inc., and Others......143
Table 143: Market Shares of Leading Ophthalmic Steroids Brands in the US (2015) - Percentage Share Breakdown by Value for Fluorometholone, Lotemax, Prednisolone and Others......144
Cardiology Therapeutics......145
Table 144: Market Shares of Leading Cardiology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......145
Cardio-Cerebral Vascular (CCV) Drugs......146
Table 145: Market Shares of Leading Cardio-Cerebral Vascular (CCV) Drugs Manufacturers in China (2015) - Percentage Share Breakdown by Value for Sihuan Pharmaceutical Holdings Group Ltd., Sanofi S.A., Qilu pharmaceutical Co., Ltd. and Others......146
Anti-viral Oral Liquids......147
Table 146: Market Shares of Leading Anti-viral Oral Liquids Producers in China (2015) - Percentage Share Breakdown by Value for Livzon Pharmaceutical Group Inc., Xiangxue Pharmaceutical Co., Ltd. and Others......147
Antibiotics......148
Table 147: Branded Acute Bacterial Skin and Skin Structure Infection Antibiotic Market by Product Worldwide (2015) - Percentage Share Breakdown by Value for Cubicin (Daptomycin), Teflaro (Ceftaroline), Tygacil (Tigecycline), and Zyvox (Linezolid)......148
Table 148: Branded Community-Acquired Bacterial Pneumonia Antibiotic Market by Product Segment Worldwide (2015) - Percentage Share Breakdown by Value for Teflaro (Ceftaroline), Tygacil (Tigecycline), and Zyvox (Linezolid)......149
Table 149: Ligand Pharmaceuticals, Inc.'s Revenue by Segment Worldwide (2014) - Percentage Market Share Breakdown by Value for Material Sales, Royalties, Collaborative R&D, and Others......150
Table 150: Ligand Pharmaceuticals, Inc.’s Sales by Business Segment Worldwide (2013) in Percentage for Ligand and CyDex......151
Table 151: Ligand Pharmaceuticals Inc.’s Revenue by Category Worldwide (2011-2013) in US$ Thousands for Royalties, Material Sales and Collaborative Research and Development and Other Revenues......152